Hypoglycemic effect of formulation containing hydroethanolic extract of Calophyllum brasiliense in diabetic rats induced by streptozotocin  by de Oliveira Carvalho, Helison et al.
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Diabetes  mellitus  is  a chronic  and  severe  metabolic  dysfunction,  it’s slow  and  progressive  evolution  inter-
feres directly  in  the  metabolism  of carbohydrates,  fats  and  proteins,  causing  hyperglycemia,  glycosuria,
polydipsia,  hyperlipidaemia,  among  others.  The  aim  of  this  study  was  to  evaluate  the  antidiabetic  effect  of
hydroethanolic  extract  and  granulated  of  Calophyllum  brasiliense  Cambess.,  Clusiaceae,  species  in diabetic
rats as well  as  it’s biochemical  parameters.  The  results  demonstrated  that both  the  pharmaceutical  forms,
hydroethanolic  extract  and  granulated,  were  able  to reduce  signiﬁcantly  (p < 0.001)  hyperglycemia  and
glycosuria,  in  addition  to  improve  polydipsia,  polyuria,  and  weight  loss.  Treatments  using  hydroethano-iabetes mellitus
olyphenols
lic extract  and  granulated  were  also  able  to  reduce  signiﬁcantly  levels  of  triacylglycerides,  cholesterol
and  low-density  lipoprotein,  as  well  as  the  transaminases,  urea  and  creatinine  levels.  Therefore,  it is
concluded  that  these  pharmaceutical  forms  have  anti-diabetic  effect  and  act improving  the  biochemi-
cal  parameters,  this  effect  is probably  due  to the  high  content  of  polyphenolic  compounds  found  in  the
formulations.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ntroduction
Calophyllum brasiliense Cambess. (Cb) species belongs to Clu-
iaceae family; it can be found spontaneously throughout Latin
merica, with predominance of the species in regions such as
mazon and Atlantic Forest. Pharmacologically, is used for several
iseases such as diabetes, bronchitis, liver disorders, gastrointesti-
al diseases, pain, inﬂammation, hypertension and rheumatism
Silva et al., 2001).
Diabetes mellitus (DM) is a chronic and severe metabolic dys-
unction, it’s slow and progressive evolution interferes directly in
he metabolism of carbohydrates, fats and proteins and is char-
cterized by absent or decreased production of insulin and/or its
ailure to properly exercise their effects on cells, leading mainly to
yperglycemia, glycosuria, polyuria, polydipsia, among others. DM
s not a single disease but a group of several metabolic disorders
∗ Corresponding author.
E-mail: farmacos@unifap.br (J.C. Carvalho).
http://dx.doi.org/10.1016/j.bjp.2016.04.004
102-695X/© 2016 Sociedade Brasileira de Farmacognosia. Published by Elsevier Edit
reativecommons.org/licenses/by-nc-nd/4.0/).that have in common hyperglycemia and dyslipidemia, and lead to
serious complications causing damage to many organs, especially
the eyes, kidneys, nerves, heart and blood ducts, making DM the
seventh cause of death in developed countries (Ada, 2011; Sacks
et al., 2002).
There is a growing demand by the world population for medici-
nal plants, where about 65–80% of the people use plants because of
poverty, precarious health system or the easy access to these nat-
ural products that are sold in street markets and popular markets
(Calixto, 2000). Therefore, studies of new anti-DM drugs have been
conducted with special focus on medicinal plants; a good exam-
ple is the plant Galega ofﬁcinalis that led to the development of
Metformin, an oral hypoglycemic drug (Noel et al., 1997).
Phytotherapics are developed by technological processes from
vegetable raw materials, and among the main pharmaceutical
forms produced, lyophilized dry extracts and granulated, which
can be intermediate or ﬁnal formulations for obtaining tablets and
capsules, are found (Carvalho et al., 2013).
The aim of this study was  to evaluate the antidiabetic effect
of hydroethanolic extract and granulated of Cb species and
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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iochemical parameters of normal and diabetic rats induced by
treptozotocin.
aterials and methods
lant material
Stem barks of Calophyllum brasiliense Cambess., Clusiaceae, was
ollected in the municipality of Ferreira Gomes, Amapá State, Brazil
0.859831 N and −51.158938 W).  The fertile material was  identiﬁed
n the Herbarium of the Instituto de Estudos e Pesquisas do Estado
o Amapá, with 0598AP as number of voucher specimen.
btaining the C. brasiliense hydroethanolic extract
To obtain the C. brasiliense hydroethanolic extract (ECb), 2 kg
f crushed and milled hulls were subjected to maceration in 70%
ydroethanol solution at 45 ◦C for 4 days in a ratio of 1:8 (w/v). The
xtractive solution was ﬁltered through ﬁlter paper and concen-
rated on rotaevaporator Model Q.218.2 (Quimus Ltda, São Paulo,
razil) at a temperature of 40 ◦C until complete evaporation of the
olvent, yielding 32.80%. Later it was lyophilized to complete elim-
nation of water, with ﬁnal yield of 7%.
btaining granulated of C. brasiliense extract (GCb)
The granule was obtained by manual mixing for granulating
sing the following combination of excipients and extract: 21.80%
vicel® cellulose (Sigma–Aldrich Co., St. Louis, USA), 3.87% magne-
ium stearate Riedelde Haën® (Sigma–Aldrich Co., St. Louis, USA),
3.35% lactose monohydrate D-Vetec® (Vetec Fine Chemicals Ltd.,
io de Janeiro, Brazil) 6.9% corn starch Duryea® (Unilever Brazil
ndustrial Ltda, Pernambuco, Brazil), 28.5% water and 26.64% dry
Cb (Carvalho et al., 2013).
uantitative analysis of polyphenols and total tannins in ECb and
Cb
In analysis of polyphenols and total tannins 0.750 g of
yophilized ECb and 2.81 g of GCb equivalent to 0.750 g of ECB
ere used. Subsequently we used the reduction of phosphomolyb-
otungstic acid technique in an alkaline medium (20% sodium
arbonate). Later the absorbance was measured at 760 nm in
V-VIS model UVmini-1240 spectrophotometer (Shimadzu Corpo-
ation, Kyoto, Japan) (Sá et al., 2015).
Levels of polyphenols and tannins were calculated from the
bsorbance submitted to the equation of the straight obtained
y the standard curve of the pyrogallic acid in concentrations of
.02–0.10 mg  ml−1 in reaction with the phosphomolybdotungstic
cid in an alkaline medium, lyophilized bovine serum albumin
as used to complexation with tannin. The percentage of polyphe-
ols and tannins was obtained applying the formula described by
arvalho et al. (2013).
Pf = x (mg/ml) · FD · 100
m (mg)
here %Pf = polyphenols percentage; x = sample concentration
btained in straight equation; DF = dilution factor of the solution;
 = mass of the sample.
nimals used in the studyWistar male rats were used, weighing around 210 ± 30 g, dur-
ng the animals activities were placed in individual metabolic
ages stainless steel, measuring 60 cm × 50 cm × 22 cm,  kept in air-
onditioned environment with temperature around 25 ± 3 ◦C and de Farmacognosia 26 (2016) 634–639 635
humidity of 50 ± 10%, photoperiod of 12 h light and dark, fed with
standard feed for rodents and water ad libitum.  This study was
approved by the Ethics Committee of the Federal University of
Amapá under the Protocol 002A/2012 August 6, 2012.
Oral test for glucose tolerance (OTGT)
To determine glucose tolerance, hyperglycemia was induced in
normoglycemic and diabetic rats with 16 h of fasting by admin-
istering by mouth of a glucose solution of 4 g/kg of body weight
30 min  after treatment. Blood glucose levels were assessed at 0, 30,
60, 90, 120 and 180 min. The animals were divided into ﬁve groups
(n = 5), a diabetic group treated with distilled water 0.5 ml/animal
(DTA), the group treated with glibenclamide by mouth 3 mg/kg
(GBC), diabetic group treated with GCb by mouth 500 mg/kg, dia-
betic group treated with ECb by mouth 500 mg/kg, non-diabetic
group of animals treated with distilled water 0.5 ml/animal (NDC).
Induction of Diabetes mellitus
The induction of diabetes was  performed in animals after 16 h
fasting period, by intraperitoneal injection of streptozotocin (STZ)
(SIGMA-Aldrich Inc., St. Louis, MO,  USA) dissolved in 0.01 M sodium
citrate buffer (pH 4.5), with a dose of 55 mg/kg in a volume of
1 ml/kg body weight. Four days after STZ injection, animals were
considered diabetic with blood sugar >300 mg/dl urine glucose
>100 mg/dl, polydipsia and polyuria. The animals were divided
into ﬁve groups (n = 5), a diabetic group treated with distilled
water 0.5 ml/animal (DTA), the group treated with glibenclamide
by mouth 3 mg/kg (GBC), diabetic group treated with GCb by
mouth 500 mg/kg, diabetic group treated with ECb by mouth
500 mg/kg, animals and non-diabetic group treated with distilled
water 0.5 ml/animal (NDC).
Development and experimental evaluation
Diabetic animals were kept in metabolic cages during the 30
days of treatment, where they were evaluated daily, body weight,
water intake, food intake, and urine volume. Glyemia and gly-
cosuria were evaluated every ﬁve days, the blood collection was
performed by retrorbital plexus and glucose levels evaluated by
photocolorimetric method glucose-oxidase (Glucox 500, Doles®
Reagents and Equipment Lab. Ltda., Goiânia-GO, Brazil). On the
30th day of treatment was held blood collection for biochemical
analysis of total protein, total triacylglycerides, total cholesterol,
high density lipoprotein (HDL), low-density lipoprotein (LDL), urea,
creatinine, transaminase glutamic oxaloacetic and glutamic pyru-
vic transaminase. All tests were performed using reagents Doles®
Reagents and Equipment Lab industry. Ltda. (Goiânia, GO, Brazil)
and the samples analyzed in UV-VIS model UVmini-1240 (Shi-
madzu Corporation, Kyoto, Japan).
Statistical analysis
We used analysis of variance (ANOVA) followed by Tukey’s
test, results with signiﬁcance level of p < 0.05 were considered sta-
tistically signiﬁcant. GraphPad Instat® and Prism® (version 5.03)
softwares were used for analyzes.
Results
Quantiﬁcation of polyphenols and total taninsWith the equation of the straight y = 10.64x  − 0020 (Fig. 1) it
was possible to realize the quantiﬁcation of polyphenols and total
tannins equivalents to pyrogallic acid, where the levels present in
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Fig. 1. Standard curve pyrogallic acid by spectrophotometry ( = 760 nm)  at con-
centrations from 0.02 to 0.10 mg  ml−1, straight line equation y = 10.64x  − 0020, the
correlation coefﬁcient r2 = 0.9964.
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iabetic in the TOTG. Signiﬁcance: **p < 0.01 and ***p < 0.001, Compared with DTA
roup. Values express the mean ± SD (n = 5/group).
he ECb were 0.025 ± 0.0019 mg  ml−1 representing 8.36% of total
olyphenols and 0.016 ± 0.0014 mg  ml−1 in of tannins with 5.33%.
n GCb polyphenols and total tannins contents were 0.021 ± 0.0023
nd 0.014 ± 0.0017 mg ml−1 with percentages of 7% and 4.66%
espectively.
ral test for glucose tolerance (OTGT)
In the OTGT performed in normal and diabetic mice (Fig. 2), all
roups presented a reduction of blood glucose levels in all analyzed
imes with exception of the DTA group. The groups of diabetic rats
reated with GCb and ECb reduced blood sugar levels signiﬁcantly
p < 0.001) when compared to the DTA group, reaching 28.98%
144 ± 6.9 mg  dl−1) and 41.86% (208 ± 13.58 mg  dl−1) of reduction
n the end of the analysis period respectively. The group treated
ith the standard drug (GBC) also presented statistically signiﬁcant
p < 0.001), with glucose reduction values of 288 ± 13.46 mg  dl−1,
quivalent to 57.95%. The NDC group presented the characteristic
roﬁle of non-diabetic animals, with peak glucose levels at 60 min
nd then decrease in subsequent times.reatment effect on clinical parameters
The DTA group presented a wide variation in the evaluated clin-
cal parameters (Table 1), compared to the NDC group is observedFig. 3. Effect of treatments on glucose levels in urine of diabetic and non-diabetic
mice. Signiﬁcance: **p < 0.01 and ***p < 0.001 Compared with DTA group. Values
express the mean ± SD (n = 5/group).
that the animals in DTA group lost weight, increased feed intake
(polyphagia), water intake (polydipsia) and urination (polyuria)
signiﬁcantly (p < 0.05 and p < 0.001), these are typical symptoms
of diabetes in untreated individuals. From the treatment with
standard drug (GBC) and oral formulations, extract (ECb) and
granulated (GCb), it was  noted that these treatments were able
to improve the clinical parameters of diabetic animals signiﬁ-
cantly (p < 0.001) when compared with the DTA group. Regarding
the weight development, an increase of body weight of 11.76%
(GBC), 18.09% (GCb) and 14.02% (ECb) was  observed, there were no
signiﬁcant ﬁndings about polyphagia because the diabetic animals
had food consumption values very close. Regarding polydipsia and
polyuria, signiﬁcant reductions (p < 0.001) were observed, where
the GBC group presented reductions of 41.81% and 63.10%, the GCb
group presented 44.27% and 55.33% and the ECb group 47.55% and
53.39% respectively.
Effect of treatment on glycosuria and glycemia
From the determination of glucose levels in urine (Fig. 3), it
was observed that the non-diabetic group (NDC) presented an
average of 7.12 ± 3.51 mg  dl−1, but the DTA group showed high val-
ues of average, presenting 442.33 ± 44.6 mg  dl−1. When ECb and
GCb treated groups are compared to DTA, a signiﬁcant reduction
(p < 0.001) in glucose excretion could be observed after treat-
ment, with reductions of 42.80% and 34.33% respectively. The
group treated with GBC also presented a signiﬁcant reduction with
p < 0.001, representing a decrease of 64.83%. The evaluation of blood
glucose (Fig. 4) showed that the NDC group presented a glycemia
mean of 160.77 ± 08.6 mg  dl−1 whereas DTA group presented very
high blood glucose levels with a mean of 455.08 ± 18.4 mg  dl−1.
When compared to the GBC groups, GCb and ECb with the DTA
group after treatment, it was observed that there was a signiﬁcant
reduction in blood glucose levels with p < 0.001, corresponding to
32.19% reductions, 18.88% and 20.89%, respectively.
Effect of treatments on biochemical parameters
Biochemical results demonstrated that DTA group presented
signiﬁcant increase (p < 0.001) in practically all biochemical param-
eters when compared to the NDC group, with the exception only
of total proteins that presented signiﬁcant reduction and HDL  that
did not show abnormal values (Table 2). Treatments with GCb and
ECb were able to signiﬁcantly reduce (p < 0.001) levels of triacyl-
glycerides, cholesterol and LDL, as well as reduced transaminases
H. de Oliveira Carvalho et al. / Revista Brasileira de Farmacognosia 26 (2016) 634–639 637
Table  1
Effect of treatments for 30 days on MD  clinical parameters in animals induced with streptozotocin (weight development, polyphagia, polydipsia and polyuria).
Clinical parameters Groups
NDC DTA GBC GCb ECb
Body weight (g/day) 275 ± 6.4a 221 ± 5.8 247 ± 5.1a 261 ± 7.3a 252 ± 6.4a
Consumption Ration (g/day) 30 ± 5.2b 40 ± 4.1 35 ± 3.3 36 ± 3.7 37 ± 5.5
Water  intake (ml/day) 46 ± 5.3a 122 ± 15.2 71 ± 13.4a 68 ± 8.1a 64 ± 9.7a
Urine volume (ml/day) 12 ± 5.7a 103 ± 8.9 38 ± 6.2a 46 ± 5.8a 48 ± 6.5a
The data represent mean ± SD (n = 5/group).
a p < 0.001 represents a statistically signiﬁcant results compared with the DTA group.
b p < 0.05 represents a statistically signiﬁcant results compared with the DTA group.
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evels, creatinine and urea, acted increasing serum levels of total
rotein. In the group treated with GBC was also possible to observe
igniﬁcant improvement (p < 0.001) in the biochemical parameters,
ith the exception of transaminase AST.
iscussion
Several studies have been developing and standardizing formu-
ations based on plant extracts in order to make such extracts a
ore technological pharmaceutical product and optimize its phar-
acological effects (Linden et al., 2000; Sartori et al., 2003; Carvalho
t al., 2013).
In this study, the ECb and GCb formulations were standard-zed as the determination of polyphenols and total tannins, where
howed high content of these substances collaborating with the
esults obtained by Carvalho et al. (2013), but the granule pro-
uction technique (GCb) from ECb demonstrated a slight decrease
able 2
ffect of treatments for 30 days on biochemical parameters of diabetes in STZ-induced an
Biochemical parameters 
NDC DTA 
Total proteins (g/dl) 6.80 ± 0.12a 4.73 ± 0.27 
Triacylglycerides (mg/dl) 82.4 ± 8.8a 241.2 ± 24.7 
Urea (mg/dl) 45.7 ± 4.9a 93.2 ± 13.2 
Creatinine (mg/dl) 0.56 ± 0.03a 0.94 ± 0.08 
Total Cholesterol (mg/dl) 59.7 ± 5.5a 165.1 ± 16.4 
HDL (mg/dl) 37.1 ± 4.6 34.1 ± 8.9 
LDL  (mg/dl) 20.1 ± 6.1a 72.7 ± 7.5 
AST (U/dl) 54.5 ± 4.4a 79.2 ± 6.7 
SGPT (U/dl) 65.4 ± 6.7a 94.3 ± 5.4 
he data represent the mean ± standard deviation (n = 5/group).
a p < 0.001 represents a statistically signiﬁcant results compared with the DTA group.
b p < 0.05 represents a statistically signiﬁcant results compared with the DTA group.of 1.36% in this content, this decrease was possibly due to the
great oxidative ease of these phenolic substances (Robards et al.,
1999).
The great antioxidant potential of medicinal plants especially
those with large content of polyphenolic compounds has been
proven, these antioxidant plants has gained an important role as
a source of treatment for diseases that present high production of
free radicals (FR), especially metabolic and genetic disorders related
diseases as diabetes, dyslipidemia and cancer. Among the antiox-
idant phenolic compounds we  can highlight, phenolic acids,
ﬂavonoids, tannins, coumarins and carotenoids (Marles and
Farnsworth, 1995; Perez et al., 1998; Ojewole, 2002; Aslan et al.,
2010).
The OTGT is a test that evaluates the ability of antidiabetic drugs
to reduce sharply the postprandial glycemia, examples of drugs
that reduce blood glucose in this test are those who  work directly
in the pancreas -cells secreting insulin such as sulfonylureas or
drugs that inhibit glucose absorption by the gastrointestinal tract
and increase the sensitivity to insulin in peripheral tissues such as
the biguanides (Souza et al., 2009).
According to Souza et al. (2009) in normoglycemic rats, the ele-
vation of postprandial glycemia after glucose overload, and the
consequent normalization to basal levels after about 120 min, fea-
turing a normal function in glucose metabolism.
In OTGT it was possible to observe that both the ECb and the GCb
presented effect on glucose metabolism, with a signiﬁcant reduc-
tion of blood glucose when compared with DTA, standard GBC drug
also signiﬁcantly reduced, but this reduction did not lead to basal
levels as observed in normoglycemic group (NDC), this reduced
effect is possibly due to destruction of pancreatic  cells by the
action of STZ, so there a is little amount insulin to be secreted by
GBC effect.
The reduction of glycemia in diabetic rats by medicinal plants
containing polyphenols and detected by OTGT has been described
in several studies (Panda and Kar, 2007; Jia et al., 2009; Li et al.,
2015) as well as the results obtained in this study using formula-
tions of C. brasiliense species.
imals. (Weight development, polyphagia, polyuria and polydipsia.).
Groups
GBC GCb ECb
6.89 ± 0.11a 7.03 ± 0.07a 6.93 ± 0.11a
163.4 ± 15.4a 131.7 ± 10.8a 159.4 ± 12.3a
62.3 ± 9.4a 64.8 ± 7.5a 59.5 ± 9.5a
0.64 ± 0.05a 0.69 ± 0.03a 0.59 ± 0.05a
115.5 ± 11.1a 98.3 ± 9.3a 96.4 ± 11.6a
30.3 ± 6.8 39.8 ± 6.1 35.6 ± 7.2
52.5 ± 6.6a 32.2 ± 5.9a 28.9 ± 6.3a
75.7 ± 3.6 59.3 ± 4.8a 65.9 ± 5.1b
76.6 ± 6.1b 79.1 ± 7.1b 74.3 ± 6.3a
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Authors report several mechanisms of action proposed for
lants containing polyphenolic compound and these can involve,
rotection of the pancreatic -cells from oxidative damage,
ncreased insulin secretion, increased sensitivity of peripheral tis-
ues in response to insulin and reduced gastrointestinal glucose
bsorption (Sezik et al., 2005; Panda and Kar, 2007).
In diabetic individuals, lack of insulin leads to various clinical
igns and symptoms, including chronic hyperglycemia, elevated
lood glucose level in urine, constant thirst (polydipsia), increased
rination (polyuria), weight loss, and severe starvation (polypha-
ia) (Mahendran et al., 2014).
Insulin deﬁciency causes hyperglycemia and when the blood
lucose level is higher than the renal ﬁltration threshold, there
s the presence of glucose in urine, as well as increased excreted
rine volume due to osmotic imbalance, hyperosmolarity, because
f high levels of circulating glucose, causes water to pass from
ntracellular to extracellular medium in order to maintain this
smotic equilibrium, intracellular dehydration is recognized by
rain osmoreceptors generating a response triggering intense
hirst, characteristic of diabetes (Lerco et al., 2003; Mahendran
t al., 2014).
Insulin is a hormone that facilitates the glucose transport into
uscle cells and adipocytes, increases the synthesis and stor-
ge of cellular proteins, muscle glycogen and triacylglycerides in
dipocytes, and decrease protein catabolism (May  and Buse, 1989).
ack of insulin causes intense catabolism process of structural
roteins and -oxidation of fatty acids to form subproducts to glu-
oneogenesis, the loss or breakdown of these structural proteins
irectly reﬂect in reduced body weight (Ramesh and Pugalendi,
006), this process can be observed in diabetic animals treated with
istilled water (DTA).
Treatment for 30 days with ECb and GCb formulations sig-
iﬁcantly reduced hyperglycemia (20.89% and 18.88%) and urine
lucose (42.80% and 34.33%) of the diabetic rats respectively, and
cted also reducing polydipsia, polyuria and loss of body mass.
The improvement of symptoms and clinical signs during 30 days
f treatment with ECb and GCb, reinforce the antidiabetic activ-
ty of Cb species, as possibly this improvement is due to the high
ontent of polyphenolic compounds, where this substances would
ct restoring the -pancreatic cells from oxidative damage caused
y STZ and consequently increasing the insulin production (Sezik
t al., 2005), these results conﬁrm the results obtained by several
uthors, who conclude that natural antioxidant substances such
s polyphenolic compounds have great potential for anti-diabetic
ctivity (Sabu et al., 2002; Hou et al., 2003; Panda and Kar, 2007;
ia et al., 2009; Alade et al., 2012).
Liver and kidneys are the main organs responsible for
etabolism and excretion of endogenous substances and xeno-
iotics, the dysfunction of these organs leads to changes in
iochemical parameters, being the markers transaminases AST and
LT who determine hepatocytes damage and elevation of creati-
ine and urea indicating renal dysfunction (Almdal and Vilstrup,
988; Ohaeri, 2001).
In DTA group, a large increase in levels of AST, ALT, creatinine and
rea were observed when compared to the NDC group, these results
ndicate that the animals in the DTA group show possible liver
nd kidney dysfunction. These changes are justiﬁed because the
nduction of diabetes by streptozotocin and the resulting chronic
yperglycemia, are factors that lead to formation of reactive oxygen
pecies (ROS), which in turn causes lipid peroxidation and damage
o cell membranes, these ROS are responsible by secondary com-
lications of diabetes mellitus such as kidney, liver, retina, blood
essels and nerve damage (Hunt et al., 1988).
Treatment of the animals using ECb and GCb were able to sig-
iﬁcantly reduce (p < 0.001 and p < 0.05) creatinine, urea, AST and
LT levels, these results demonstrate that there was  a signiﬁcanta de Farmacognosia 26 (2016) 634–639
reduction in liver damage and are in line with results obtained by
(Ohaeri, 2001; Ramesh et al., 2010). The improvement of renal dys-
function can be justiﬁed by the increase in total protein levels, as
in diabetic individuals nephropathy is the main factor for protein
excretion in urine, these results are consistent with those obtained
by Bakris (1993) and Tuvemo et al. (1997).
The results of renal and hepatic biochemical parameters also
reinforce the lack of toxicity of the doses of the formulations used
in this study, and corroborate with the results obtained by Oliveira
et al. (2014), which demonstrate that the treatment for 30 days
with 500 mg/kg of ECB, no showed signs of toxicity in rats.
Diabetes is a disease that has a great inﬂuence on lipid
metabolism causing increases in serum triacylglycerides, choles-
terol and lipoproteins, this fact can be observed in DTA group
where is possible to see a very signiﬁcant increase (p < 0.001) in
triacylglyceride, cholesterol and LDL serum values. Treatment with
ECb and GCb were able to reduce the increase of the triacylglyc-
erides levels, cholesterol and LDL, but there was no signiﬁcance
in the results of HDL, similar results were obtained with experi-
mental diabetic mice after treatment with plant extracts containing
polyphenols, where a signiﬁcant reduction in lipid levels could be
observed (Ramadan et al., 2009; Islam, 2011).
The increase in lipid levels on diabetes are mainly responsible for
mediating the formation of RL by peroxidation of unsaturated fatty
acids, cholesterol and lipoproteins, increased lipid peroxidation
leads to membrane damage and consequently organs dysfunction
being this an important risk factor for atherosclerosis and coronary
artery disease (Maghrani et al., 2004; Alfy et al., 2005).
Decrease on lipid levels and consequently the reduction of lipid
peroxidation is improved due to the high antioxidant potential
of polyphenolic compounds that act by mechanisms of reaction
inhibition in the peroxidation chain and can reduce complica-
tions resulting from diabetes (Kamalakkannan and Prince, 2006;
Mahendran et al., 2014).
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